# Clear cell renal cell carcinoma combined with intravascular large B-cell lymphoma: a case report and review of the literature

**Authors:** Zhen Zheng, Yuwei Shou, Jingqi Zhou, Enjie Liu, Minglei Yang, Xiu Liu, Jianguo Wei

PMC · DOI: 10.3389/fonc.2026.1788733 · Frontiers in Oncology · 2026-02-18

## TL;DR

This paper reports a rare case of kidney cancer combined with a type of lymphoma, highlighting the challenges in diagnosis and treatment.

## Contribution

The paper presents a rare case of ccRCC combined with IVLBCL, emphasizing the diagnostic difficulties and clinical implications.

## Key findings

- The lymphoma component was confined within the blood vessels of the RCC, leading to potential misdiagnosis.
- The patient showed favorable outcomes after surgery and chemotherapy with 16 months of follow-up.
- The case highlights the need for increased awareness among physicians to improve diagnosis and prognosis.

## Abstract

Clear cell renal cell carcinoma (ccRCC) combined with intravascular large B-cell lymphoma (IVLBCL) is an extremely rare collision tumor, and its coexistence is often missed or misdiagnosed, making clinical diagnosis and treatment notably difficult.

We present the case of a 68-year-old male, in whom imaging revealed a nodular soft tissue density shadow in the parenchyma of the left kidney. Immunohistochemistry and molecular testing confirmed the combination of ccRCC and IVLBCL. Following surgery, the patient underwent comprehensive examinations, including bone marrow biopsy and cytology, to rule out systemic lymphoma involving the kidneys. The patient received postoperative chemotherapy and was still in a favorable condition after 16 months of follow-up.

In the ccRCC combined with IVLBCL, the lymphoma component is confined within the blood vessels of the RCC, making it extremely prone to misdiagnosis, which can lead to a poor prognosis. This case report presents an incidental finding of ccRCC combined with IVLBCL, aiming to raise physician awareness and provide valuable clinical references.

## Linked entities

- **Diseases:** clear cell renal cell carcinoma (MONDO:0005005), intravascular large B-cell lymphoma (MONDO:0020324)

## Full-text entities

- **Genes:** CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CD34 (CD34 molecule) [NCBI Gene 947], SLC4A1 (solute carrier family 4 member 1 (Diego blood group)) [NCBI Gene 6521] {aka AE1, BND3, CD233, CHC, DI, EMPB3}, CLTA (clathrin light chain A) [NCBI Gene 1211] {aka LCA}, PWWP3A (PWWP domain containing 3A, DNA repair factor) [NCBI Gene 84939] {aka EXPAND1, HSPC211, MUM-1, MUM1}, TFEB (transcription factor EB) [NCBI Gene 7942] {aka ALPHATFEB, BHLHE35, TCFEB}, CA9 (carbonic anhydrase 9) [NCBI Gene 768] {aka CAIX, MN}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}
- **Diseases:** diabetes mellitus (MESH:D003920), angiolipoma (MESH:D018206), Tumor (MESH:D009369), dyspnea (MESH:D004417), inflammatory (MESH:D007249), retroperitoneal lymphadenopathy (MESH:D012186), hemophagocytic syndrome (MESH:D051359), hematuria (MESH:D006417), large cell lung cancer (MESH:D055752), angiomyolipoma (MESH:D018207), fever (MESH:D005334), hematologic tumor (MESH:D019337), kidney tumor (MESH:D007680), vomiting (MESH:D014839), squamoid alveolar RCC (MESH:D002282), Kaposi sarcoma (MESH:D012514), lower back pain (MESH:D017116), dysuria (MESH:D053159), nausea (MESH:D009325), hemorrhage (MESH:D006470), pneumonia (MESH:D011014), fatigue (MESH:D005221), primary (MESH:D010538), lymphangioma (MESH:D008202), cerebral infarction (MESH:D002544), XL (MESH:D000080345), cough (MESH:D003371), gastrointestinal stromal tumors (MESH:D046152), metastases (MESH:D009362), meningioma (MESH:D008579), necrosis (MESH:D009336), hemangioma (MESH:D006391), DLBCL (MESH:D016403), Clear cell renal cell carcinoma (MESH:D002292), B-cell lymphoma (MESH:D016393), breast cancer (MESH:D001943), IVL (MESH:D008223), systemic endotheliomatosis (MESH:D015619), ovarian carcinoma (MESH:D010051)
- **Chemicals:** CVAD (MESH:C064396), rituximab (MESH:D000069283), CHOP (MESH:C036337), H&amp;E (MESH:D006371), R-CHOP (-), Hematoxylin (MESH:D006416), eosin (MESH:D004801)
- **Species:** human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956660/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956660/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956660/full.md

---
Source: https://tomesphere.com/paper/PMC12956660